A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 Age 16 Years or Greater

Trial Profile

A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 Age 16 Years or Greater

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Plexiform neurofibroma
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Sep 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2019.
    • 26 Sep 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
    • 10 Sep 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top